Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380242 | 0.81 | TRPV1 (0.38) | LMNAGRM4KMT2AMAPK1L3MBTL1 | |
| SCHEMBL2379941 | 0.79 | NPC1 (0.42) | LMNAKMT2AMEN1MAPK1L3MBTL1 | |
| SCHEMBL4035192 | 0.75 | ABCB1 (0.37) | LMNAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL9200260 | 0.74 | PTPN1 (0.42) | LMNAKMT2AMEN1MAPK1L3MBTL1 | |
| SCHEMBL2378913 | 0.73 | NPC1 (0.44) | LMNAGRM4KMT2AMEN1MAPK1 | |
| SCHEMBL2378897 | 0.72 | TDP1 (0.40) | SMN1; SMN2MAPT | |
| SCHEMBL2378290 | 0.71 | YAP1 (0.40) | LMNAKMT2AMEN1MAPK1L3MBTL1 | |
| SCHEMBL2379132 | 0.70 | HDAC3 (0.42) | SMN1; SMN2 | |
| SCHEMBL3548983 | 0.69 | IRAK4 (0.53) | LMNAKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL22987944 | 0.69 | CTSD (0.57) | LMNAKMT2AMEN1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-7749995-B2 | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| EP-2023934-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134149-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134149-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | LMNA 780/4885GRM4 4774/4885KMT2A 3301/4885 |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | LMNA 780/4885GRM4 4774/4885KMT2A 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.